Language in the Mathematics Classroom: An introduction to the papers and presentations within ETC 7

Research considering the role of language in the teaching and learning of mathematics continues to grow and develop, drawing on a range of theoretical, methodological and pedagogical approaches. In this introduction, we detail the discussions had and issues raised at the 7th ERME Topic Conference as a result of the bringing together of the theoretical perspectives, foci and findings of the papers presented that are included in these proceedings. These rich discussions also raised new challenges for those researching language and mathematics and identified new possibilities for the future work of the Mathematics and Language thematic working group. Keywords: Language and mathematics, multilingual contexts, meaning-making, interaction<br/

Begeleiden en beoordelen van ontwerpgericht onderzoek in studio’s = Supervising and assessing design-based research in studios

In het vernieuwde vak “Educational Design Research (EDR)” van de universitaire lerarenopleiding, Master Educatie in de Bètawetenschappen werken studenten samen volgens de cyclus van EDR (McKeeney &amp; Reeves, 2019) rondom thema’s die leven in scholen uit ons netwerk. Uit een verkennende fase, waarin praktijk en literatuur centraal staan, volgen eerste ontwerpprincipes. Het ontwerp wordt ontwikkeld en verantwoord. Ten behoeve van de implementatie en evaluatie wordt een plan gemaakt. Uit de implementatie en evaluatie volgt een eindverslag. Deze groepsproducten leiden tot een groepscijfer. Daarnaast hebben we in ons ontwerp van EDR een werkwijze ontwikkeld rondom de persoonlijke ontwikkeling van de studenten, die uiteindelijk meeweegt in de bepaling van het individuele cijfer. In deze Ontmoeting werken we aan de hand van het wereldcafé aan het bespreken van deze werkwijze; de manier waarop studiobegeleiders zowel begeleider als beoordelaar zijn; en de rol van studenten en scholen in dit geheel. Ieder onderwerp van discussie wordt aan de hand van drie opeenvolgende vragen besproken: knelpunten, oplossingen, randvoorwaarden. De opbrengst gaat in op het (door)ontwikkelen van dit proces. Daarnaast willen we andere lerarenopleidingen ondersteunen die met vergelijkbare processen werken en leren van/met deze ervaringen

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Tweetaligheid vergroot begrip

Content-and-Language-Integrated-Learning (CLIL) – vakles in een andere taal – wordt steeds relevanter in Nederland. Maar het flexibel wisselen tussen talen, bijvoorbeeld bij wiskunde, kan een beter begrip opleveren